Clinical Trial Update: Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or Adolescents [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating pazopanib in combination with TGI/CIV for recurrent or refractory rhabdomyosarcoma in children and adolescents; currently recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rhabdomyosarcoma

Drugs mentioned

• Pazopanib (Pazopanib)
• TGI/CIV

Snippet

Sponsor: Shandong Cancer Hospital and Institute | Conditions: Rhabdomyosarcoma, Recurrent, Refractory | Phase 2 | Status: RECRUITING